Navigation Links
Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Date:11/13/2012

MOUNTAIN VIEW, Calif., Nov. 13, 2012 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome." Four clinical trial sites have been selected in the United States: Lucile Packard Children's Hospital, Stanford University Medical Center – Palo Alto, California; Akron Children's Hospital – Akron, Ohio; Seattle Children's Hospital – Seattle, Washington; and Texas Children's Hospital, Baylor University – Houston, Texas.

The trial is a placebo-controlled study lasting six months, and then extending an additional six months, during which all subjects will receive EPI-743. Subjects must be between one and twelve years old, possess genetic confirmation of Leigh syndrome, and meet certain disease severity criteria. More information on the study specifics is available on ClinicalTrials.gov.

The primary endpoint of the clinical trial is the Newcastle Paediatric Mitochondrial Disease Scale. Secondary endpoints include neurologic, muscular, imaging, and biomarker indices. The study design was based on positive phase 2A data recently reported in the journal Molecular Genetics and Metabolism, "EPI-743 reverses the progression of the pediatric mitochondrial disease- genetically defined Leigh Syndrome" 107 (2012) 383-388.

Leigh Syndrome

Leigh syndrome is an inherited lethal, progressive, predominately pediatric, neuromuscular disorder for which there are no approved treatments. Initially described in 1951, the hallmarks of the disease include death of central nervous system regions responsible for the control of breathing and coordination of movement. Leigh syndrome is a member of a larger family of diseases called mitochondrial disease, which share as a common biochemical mechanism defects in cellular energy metabolism.

EPI-743

EPI-743 is
'/>"/>

SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
2. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
5. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
6. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
7. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
8. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Agreement reinforces ViiV ...   ViiV Healthcare and Desano Pharmaceuticals (Desano) today ... China of dolutegravir. The agreement will offer ... and will allow ViiV Healthcare to offer a competitive supply ... Tivicay®) for China and a number ...
(Date:7/1/2015)... , July 1, 2015 The ... group of state and regional professional rheumatology societies, ... of rheumatologists that explored perceptions of biosimilars and ... patients. Biosimilars are medicines that ... medicines. They are notably different from generic medications ...
(Date:7/1/2015)... , July 1, 2015 Jazz Pharmaceuticals plc ... be webcasting its corporate presentation at the Cantor Fitzgerald Healthcare ... Russell Cox , executive vice ... the company and a business and financial update on Wednesday, ... IST.  A live audio webcast of the ...
Breaking Medicine Technology:ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... Chinese subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner"), acquired ... ("Charles River") Shanghai research facility. ...
... 24, 2011 Codexis, Inc. (Nasdaq: ... launch, its Codex® Screening Kits are in use ... pharmaceutical companies worldwide.  The announcement was made at ... here this week.   Codex® Screening ...
Cached Medicine Technology:ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 250 Pharma Companies Worldwide Now Use Codexis In Process Development 2
(Date:7/2/2015)... York (PRWEB) , ... July 02, 2015 , ... It’s no secret that what we consume can have an effect ... many people can easily feel dehydrated or perhaps even undernourished if not eating enough of the ... it can be an easy time of year to overdo it on the food front as ...
(Date:7/2/2015)... ... July 02, 2015 , ... Denver-based SlimGenics Weight Control ... was named No. 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz ... been recognized. The award identifies outstanding woman-owned businesses that demonstrate excellence and success ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. Jian-Dong Li, a professor ... a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a ... , The grant from the National Institute on Deafness and Other Communication Disorders ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... they will welcome four new members to their industry leading Scientific Advisory Board. ...
(Date:7/1/2015)... ... , ... Dr. Surya Challa of Chesapeake Vein Center and MedSpa in Chesapeake, ... to discuss non-invasive CoolSculpting . On the show, Dr. Challa will explain how ... reduction utilizes Cryolipolysis to literally freeze stubborn, unwanted fat away and give patients the ...
Breaking Medicine News(10 mins):Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3
... Register for ... ... -- In June of 2009, the world reached a turning point in our history. The ... result of the recent contested presidential election, demonstrations and protests ensued. The government,s crack-down on ...
... National poll finds kids in poorest families feel effects most ... taking a toll on many U.S. children, especially the poor ... their children. , The poll, conducted in the United States ... worsened in the previous six months, forcing them to spend ...
... in nonsmoking patients; could be target for treatment , ... a small molecule that might play a big part ... people who have never smoked, opening up the possibilities ... microRNA miR-21 was found particularly elevated in adenocarcinomas that ...
... ... iCRco completed its annual Asia/Pacific distributor training program in Suzhou, China, with over 60 ... ... training program in Suzhou, China, with over 60 representatives in attendance., , ,This year,s ...
... , , TIJUANA, Mexico, July 17 ... Throughout Mexico, childcare center owners are being crucified unjustly. Following a ... in Hermosillo, Sonora, the entire country has risen up in arms ... Eli Grey, whose family owns multiple centers and runs Interchildren, believes ...
... July 17 The economic downturn is impacting the health of many people ... by causing people to put off getting the health care they need. , ... offering suggestions for how to get them most for your money when it ... t put off necessary treatment , Fears about possible ...
Cached Medicine News:Health News:reThinking eHealth Webinar Announced: Hospital Marketing in the eHealth Era 2Health News:Recession Takes Toll on Children's Health 2Health News:Small Molecule Might Play Big Part in Lung Cancer 2Health News:Small Molecule Might Play Big Part in Lung Cancer 3Health News:iCRco Conducts 2009 Asia/Pacific Distributor Training Program 2Health News:iCRco Conducts 2009 Asia/Pacific Distributor Training Program 3Health News:Child Care Centers Throughout Mexico Being Crucified Unjustly, Says Interchildren, Inc. 2Health News:How to Afford Health Care in Hard Times 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: